Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
TipRanks on MSN
Vizsla, Coty, Kalaris, Annexon, Brown & Brown trending
Analysts are intrested in these 5 stocks: ( ($VZLA) ), ( ($COTY) ), ( ($KLRS) ), ( ($ANNX) ) and ( ($BRO) ). Here is a breakdown of their recent ...
Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
Stocktwits on MSN
Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside
The FDA approval clears the path for a U.S. launch in January 2026. ・Trial and expanded access data showed strong response rates and short-term survival in high-risk patients. ・Yartemlea becomes the ...
Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...
SEATTLE--(BUSINESS WIRE)--Dec 24, 2025-- ...
Thinking outside the canon, and finding the gritty and the beautiful, within it. By Joshua Barone and Corinna da Fonseca-Wollheim JOSHUA BARONE Few art forms are as burdened by canons as classical ...
In the retina, age-related macular degeneration (AMD) affects the complex of photoreceptors, retinal pigment epithelium (RPE), Bruch’s membrane (BM) and the choriocapillaris, the innermost layer of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback